Inequitable Conduct: Drug Industry Implores Federal Circuit To Revise Standard For Finding Deception In Patent Prosecution
Executive Summary
The pharmaceutical industry has jumped at the opportunity to weigh in on a case that could change how courts determine whether patent owners deceived the U.S. Patent and Trademark Office in obtaining their patents
You may also be interested in...
Inequitable Conduct "Plague" Cured By Federal Circuit's Therasense Decision
Alleged infringers will have a tougher time proving that a patent applicant deceived the patent office under a new standard set by the U.S. Court of Appeals for the Federal Circuit.
Inequitable Conduct "Plague" Cured By Federal Circuit's Therasense Decision
Alleged infringers will have a tougher time proving that a patent applicant deceived the patent office under a new standard set by the U.S. Court of Appeals for the Federal Circuit.
House Patent Reform Bill: Battle Looms Over Reexam, Prior User Rights Provisions
The six-year battle over patent reform legislation is not yet over as the pharmaceutical and biotechnology industries and other leading stakeholders are unhappy with provisions in the House bill that differ from the recently passed Senate measure.